Cejka, Daniel <br/><br/>
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.  [electronic resource] 

 -  Cancer biology & therapy  Sep 2008 
 - 1377-85 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.7.9.6416  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cyclophosphamide--pharmacology<br/>Drug Therapy, Combination<br/>Enzyme Activation--drug effects<br/>Everolimus<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Ki-67 Antigen--metabolism<br/>Mice<br/>Mice, SCID<br/>Necrosis--pathology<br/>Neovascularization, Pathologic--drug therapy<br/>Random Allocation<br/>Sirolimus--analogs & derivatives<br/>Stomach Neoplasms--blood supply<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays--methods